Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down – Time to Sell?

Stoke Therapeutics, Inc. (NASDAQ:STOK) shares gapped down prior to trading on Tuesday . The stock had previously closed at $11.02, but opened at $9.82. Stoke Therapeutics shares last traded at $9.69, with a volume of 448,132 shares traded.

Analyst Ratings Changes

STOK has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Chardan Capital started coverage on Stoke Therapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $24.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $21.29.

Stoke Therapeutics Stock Performance

The stock has a market capitalization of $489.94 million, a PE ratio of -4.40 and a beta of 0.95. The firm has a 50 day moving average of $12.18 and a 200-day moving average of $13.17.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. On average, sell-side analysts predict that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 9,696 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the transaction, the general counsel now owns 35,142 shares in the company, valued at $449,114.76. This represents a 21.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the transaction, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. This trade represents a 16.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 62,849 shares of company stock valued at $809,421 in the last quarter. Company insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Lynx1 Capital Management LP lifted its position in shares of Stoke Therapeutics by 40.3% during the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after purchasing an additional 1,488,371 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its position in Stoke Therapeutics by 426.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after buying an additional 1,123,500 shares during the period. Logos Global Management LP acquired a new position in shares of Stoke Therapeutics during the second quarter worth approximately $14,186,000. Marshall Wace LLP boosted its position in shares of Stoke Therapeutics by 550.1% in the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock valued at $15,686,000 after acquiring an additional 982,451 shares during the period. Finally, RTW Investments LP grew its stake in shares of Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after acquiring an additional 427,447 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.